NEURIZON THERAPEUTICS LIMITED ASX News

16 January 2025

Neurizon updates on NUZ-001 IND Application

FDA places Neurizon's NUZ-001 IND application on clinical hold for further information.

Neurizon Therapeutics FDA Clinical Hold NUZ-001 Biotechnology ALS Treatment

Posted on: 16/01/2025

17 December 2024

Neurizon Files IND Application to Support HEALEY ALS Trial

Neurizon files IND application for NUZ-001 to begin Phase 2/3 ALS trial.

Neurizon Therapeutics ALS Treatment Biotechnology FDA Approval Clinical Trials

Posted on: 17/12/2024

15 December 2024

Positive 8-month Interim Data from OLE Study

Neurizon's NUZ-001 shows significant survival benefits for ALS patients.

Neurizon Therapeutics ALS Treatment Biotechnology Clinical Trials Neurodegenerative Diseases

Posted on: 15/12/2024

14 November 2024

Neurizon Presents Positive Preclinical Data on NUZ-001

Neurizon Therapeutics presents positive preclinical data for ALS treatment.

Neurizon Therapeutics ALS Biotechnology Neurodegenerative Diseases Stock Market News

Posted on: 14/11/2024

NUZ-001 Reduces Aggregation of Key ALS Disease Target

Neurizon's NUZ-001 shows potential in reducing ALS disease target TDP-43 aggregation.

Neurizon Therapeutics ALS Biotech Drug Development Stock Market News

Posted on: 14/11/2024